…
Owens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates in two segments, Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, including supplier management, analytics, inventory management, and clinical supply management; and various programs to provide outsourced logistics and marketing solutions to its suppliers. The Patient Direct segment provides products and services for in-home care and delivery across diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment. This segment supplies a range of other home medical equipment, patient care products, including ostomy, wound care, urology, incontinence and other products and services. It serves multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. The company was founded in 1882 and is headquartered in Richmond, Virginia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 10.89M | 276.75M | 109.91M | -28.72M | -469.19M |
| Net income | 22.39M | 221.59M | 88.07M | -22.58M | -437.01M |
| Selling general administrative | 1633.67M | 1116.87M | 1041.32M | 1023.05M | 1261.75M |
| Selling and marketing expenses | 1633.67M | - | 0.01M | 0.01M | - |
| Gross profit | 1826.35M | 1513.23M | 1280.83M | 1128.49M | 1366.96M |
| Reconciled depreciation | 228.67M | 90.62M | 93.34M | 116.68M | 101.93M |
| Ebit | 194.80M | 368.47M | 204.12M | 99.44M | 109.64M |
| Ebitda | 423.47M | 489.97M | 324.39M | 216.12M | 211.57M |
| Depreciation and amortization | 228.67M | 121.50M | 120.28M | 116.68M | 101.93M |
| Non operating income net other | - | -43.63M | -10.81M | -3.76M | - |
| Operating income | 194.80M | 368.47M | 204.12M | 99.44M | -392.17M |
| Other operating expenses | 9757.54M | 9382.77M | 8238.31M | 9107.74M | 9729.07M |
| Interest expense | 128.89M | 48.09M | 83.40M | 98.11M | 77.02M |
| Tax provision | -11.50M | 55.16M | 21.83M | -6.13M | -32.18M |
| Interest income | 128.89M | 48.09M | 83.40M | 98.11M | 70.98M |
| Net interest income | -128.89M | -48.09M | -83.40M | -98.11M | -77.02M |
| Extraordinary items | 0.00M | 0.00M | -58.20M | -39.79M | -42.35M |
| Non recurring | - | 34.08M | 37.75M | 30.05M | 501.81M |
| Income tax expense | -11.50M | 55.16M | 21.83M | -6.13M | -32.18M |
| Total revenue | 9955.48M | 9785.32M | 8480.18M | 9210.94M | 9838.71M |
| Total operating expenses | 1628.42M | 1110.68M | 1038.96M | 1025.29M | 1257.32M |
| Cost of revenue | 8129.12M | 8272.09M | 7199.34M | 8082.45M | 8471.75M |
| Total other income expense net | -183.91M | -91.72M | -94.21M | -128.16M | -501.81M |
| Discontinued operations | - | - | -58.20M | -39.79M | -42.35M |
| Net income from continuing ops | 22.39M | 221.59M | 88.07M | -34.85M | -501.38M |
| Net income applicable to common shares | 22.39M | 221.59M | 29.87M | -62.37M | -437.01M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 5386.28M | 3536.55M | 3335.64M | 3643.08M | 3773.79M |
| Intangible assets | 445.04M | 209.75M | 243.35M | 285.02M | 321.76M |
| Other current assets | 128.64M | 88.56M | 118.26M | 79.37M | 321.69M |
| Total liab | 4440.68M | 2598.05M | 2623.59M | 3180.93M | 3255.37M |
| Total stockholder equity | 945.60M | 938.50M | 712.05M | 462.15M | 518.42M |
| Deferred long term liab | - | 35.31M | 50.64M | 40.55M | 50.85M |
| Other current liab | 419.05M | 342.06M | 345.54M | 608.12M | 362.42M |
| Common stock | 152.56M | 150.87M | 146.94M | 125.69M | 124.59M |
| Capital stock | 152.56M | 150.87M | 146.94M | 125.69M | 124.59M |
| Retained earnings | 410.01M | 387.62M | 167.02M | 137.77M | 200.67M |
| Other liab | 175.78M | 144.25M | 171.91M | 121.84M | 128.56M |
| Good will | 1636.70M | 390.19M | 394.09M | 393.18M | 414.12M |
| Other assets | 150.42M | 103.57M | 246.68M | 56.36M | 136.07M |
| Cash | 69.47M | 55.71M | 83.06M | 67.03M | 103.37M |
| Cash and equivalents | 69.47M | 55.71M | 83.06M | 67.03M | 103.37M |
| Total current liabilities | 1566.47M | 1344.02M | 1345.73M | 1416.16M | 1472.01M |
| Current deferred revenue | - | 28.30M | - | - | - |
| Net debt | 2628.97M | 1054.07M | 1022.89M | 1558.46M | 1547.21M |
| Short term debt | 0.00M | 96.33M | 4.10M | 50.22M | 28.69M |
| Short long term debt | - | - | - | 50.22M | 28.69M |
| Short long term debt total | 2698.44M | 1109.78M | 1105.95M | 1625.49M | 1650.58M |
| Other stockholder equity | 418.89M | 440.61M | 436.60M | 251.40M | 238.77M |
| Property plant equipment | 858.93M | 511.24M | 460.42M | 315.43M | 386.72M |
| Total current assets | 2295.18M | 2321.81M | 2135.86M | 2407.28M | 2538.58M |
| Net tangible assets | -1174.84M | 338.57M | 74.62M | -216.04M | -217.47M |
| Net receivables | 763.50M | 681.56M | 700.79M | 674.71M | 823.42M |
| Long term debt | 2482.97M | 947.54M | 986.02M | 1508.41M | 1650.58M |
| Inventory | 1333.59M | 1495.97M | 1233.75M | 1146.19M | 1290.10M |
| Accounts payable | 1147.41M | 1001.96M | 1000.19M | 808.03M | 1109.59M |
| Accumulated other comprehensive income | -35.85M | -40.59M | -38.51M | -52.71M | -45.61M |
| Common stock total equity | - | 150.87M | 146.94M | 125.69M | 124.59M |
| Retained earnings total equity | - | 387.62M | 167.02M | 137.77M | 200.67M |
| Non currrent assets other | 150.42M | 103.57M | 101.92M | 99.96M | 112.60M |
| Non current assets total | 3091.10M | 1214.74M | 1199.77M | 1235.80M | 1235.21M |
| Capital lease obligations | 215.47M | 162.24M | 119.93M | 117.08M | - |
| Long term debt total | 2482.97M | 947.54M | 986.02M | 1508.41M | 1650.58M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -1804.48M | -53.63M | 80.07M | -51.90M | -815.83M |
| Change to liabilities | 13.65M | 3.55M | 193.24M | -235.63M | 92.18M |
| Total cashflows from investing activities | -1804.48M | -53.63M | 80.07M | -51.90M | -815.83M |
| Net borrowings | 1582.50M | -110.79M | -547.24M | -32.20M | 695.75M |
| Total cash from financing activities | 1497.11M | -129.48M | -379.39M | -130.20M | 701.07M |
| Change to operating activities | -91.54M | 0.69M | 5.28M | 104.80M | -23.60M |
| Net income | 22.39M | 221.59M | 29.87M | -62.37M | -437.01M |
| Change in cash | 14.15M | -62.47M | 49.82M | -18.68M | -1.16M |
| Begin period cash flow | 72.03M | 134.51M | 84.69M | 103.37M | 104.52M |
| End period cash flow | 86.19M | 72.03M | 134.51M | 84.69M | 103.37M |
| Total cash from operating activities | 325.01M | 124.18M | 339.22M | 166.09M | 115.59M |
| Issuance of capital stock | 0.00M | 0.00M | 189.97M | - | - |
| Depreciation | 228.67M | 90.62M | 93.34M | 116.68M | 101.93M |
| Other cashflows from investing activities | -1637.89M | -12.64M | 130.50M | -9.48M | -770.96M |
| Dividends paid | 0.00M | -0.73M | -0.65M | -5.23M | 48.20M |
| Change to inventory | 166.56M | -263.44M | -85.15M | 127.92M | -65.45M |
| Change to account receivables | 1.10M | -2.20M | -34.82M | 63.53M | 11.11M |
| Sale purchase of stock | 0.00M | 0.00M | 144.73M | - | 0.00M |
| Other cashflows from financing activities | 2657.91M | 527.59M | -16.49M | -7.18M | 765.52M |
| Change to netincome | -15.82M | 71.90M | 139.15M | 15.80M | 16.38M |
| Capital expenditures | 166.58M | 49.69M | 59.19M | 52.23M | 65.69M |
| Change receivables | - | -2.20M | -34.82M | -63.53M | -11.11M |
| Cash flows other operating | - | 2.15M | 3.60M | -104.80M | 23.60M |
| Exchange rate changes | - | - | - | - | -1.99M |
| Cash and cash equivalents changes | - | -58.93M | 39.91M | -16.01M | -1.16M |
| Change in working capital | 89.77M | -261.40M | 78.55M | 60.62M | 14.23M |
| Stock based compensation | 20.99M | 25.02M | 20.01M | 15.80M | 16.38M |
| Other non cash items | -10.45M | 78.09M | 101.90M | 52.76M | 455.09M |
| Free cash flow | 158.42M | 74.49M | 280.03M | 113.86M | 49.90M |
Sector: Healthcare Industry: Medical Distribution
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MCK McKesson Corporation |
7.55 0.71% |
1069.71 | 24.45 | 20.41 | 0.26 | 5.04 | 0.27 | 15.03 |
| COR Cencora Inc. |
-2.16 0.63% |
339.09 | 24.22 | 16.39 | 0.19 | 20.41 | 0.21 | 13.72 |
| CAH Cardinal Health Inc |
0.59 0.22% |
272.93 | 29.48 | 17.92 | 0.20 | 16.07 | 0.22 | 15.67 |
| HSIC Henry Schein Inc |
-1.30 1.53% |
83.50 | 25.89 | 15.08 | 0.72 | 3.14 | 1.00 | 13.43 |
Owens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates in two segments, Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, including supplier management, analytics, inventory management, and clinical supply management; and various programs to provide outsourced logistics and marketing solutions to its suppliers. The Patient Direct segment provides products and services for in-home care and delivery across diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment. This segment supplies a range of other home medical equipment, patient care products, including ostomy, wound care, urology, incontinence and other products and services. It serves multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. The company was founded in 1882 and is headquartered in Richmond, Virginia.
9120 Lockwood Boulevard, Mechanicsville, VA, United States, 23116
804 723 7000
22500
| Name | Title | Year Born |
|---|---|---|
| Mr. Edward A. Pesicka | Pres, CEO & Director | 1968 |
| Mr. Nicholas Joseph Pace II | Exec. VP, Gen. Counsel & Corp. Sec. | 1971 |
| Mr. Andrew G. Long | Exec. VP and CEO of Products & Healthcare Services Segment | 1965 |
| Mr. Alexander J. Bruni | Exec. VP & CFO | 1976 |
| Mr. Michael Wayne Lowry | Sr. VP, Corp. Controller & Chief Accounting Officer | 1962 |
| Alex Jost CPA | Director of Investor Relations | NA |
| Ms. Tammy Gomez | Exec. VP & Chief HR Officer | NA |
| Mr. David Myers | Sr. VP & Chief Procurement Officer | NA |
| Mr. Jonathan A. Leon | Sr. VP & Corp. Treasurer | 1967 |
| Mr. Daniel J. Starck | Exec. VP, Pres of Patient Direct & CEO of Apria | 1967 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.